论文部分内容阅读
从2012年11月4日至今,IPO在经历了中国证券史上最长的空窗期后,终于进入了重启倒计时。目前,763家排队上市的公司中,已过会的共有83家。其中,生物医药属于最被看好的板块之一,因为普遍认为该产业发展前景良好,可持续发展和赢利能力都很突出,投资者会给予较多关注。然而,生物医药欣欣向荣的背后却是隐忧重重。中国拥有大小医药企业4000多家,却没有一家能进世界500
From November 4, 2012 to the present, after experiencing the longest window period in the history of Chinese securities, IPO finally entered the countdown to restart. At present, there are 83 out of 763 companies queuing to go public. Among them, biomedicine is one of the most favored sectors, because the industry generally believe that the prospects for the development of good, sustainable development and profitability are very prominent, investors will give more attention. However, behind the prosperous biomedicine is a hidden concern. China has more than 4,000 large and small pharmaceutical companies, but none of them can enter the world 500